The objective of genetic screening is informed choice. The UK Confidential Enquiry into Genetic Counselling by Non-Geneticists (CEGEN) aims to assess the attainment of this objective at the community level. Antenatal screening for thalassaemias and sickle cell disorders has long been standard practice in the UK. National registers of patients and of prenatal diagnoses identify all known conceptions with a fetus with thalassaemia major, and their outcomes. CEGEN viewed the obstetric records of women with an affected pregnancy in 1990–1994: risk had been detected in only half the cases. Hence nationally only half the couples at risk for thalassaemia have access to an informed choice. Most uninformed couples were British Pakistanis: the records revealed that screening had a low priority because of an assumption that they would decline genetic abortion for religious reasons. CEGEN showed that in fact over 70% of British Pakistanis request prenatal diagnosis, providing it is offered in the first trimester. This work demonstrates the power of a confidential enquiry based on genetic diagnosis registers for both assessing the delivery of screening, and eliciting the preferences of the population. The results offer an appropriate guide to acceptable service development.

1.
WHO: Proposed international guidelines on ethical issues in medical genetics and genetic services (WHO/HGN/GL/ETH/98.1).
2.
Proceed with Care: Final report of the Royal Commission on New Reproductive Technologies. Ottawa, Canada Communications Group-Publishing, 1993.
3.
Fletcher JC, Berg K, Tranoy KE: Ethical aspects of medical genetics. A proposal for guidelines in genetic counselling, prenatal diagnosis and screening. Clin Genet 1985;27:199–205.
4.
WHO: Community approaches to the control of hereditary diseases. Report of a WHO Advisory Group on Hereditary Diseases. Geneva, 1985, unpubl WHO document (HMG/AG/85.10).
5.
The NHS plan: A Plan for Investment, a Plan for Reform. Ensuring a Healthy Start in Life. London, Her Majesty’s Stationery Office, 2000, chapt 13 (also available at www.nhs.uk/nhsplan).
6.
Modell B, Darlison M: New developments in genetics for the new millennium: The concept of clinical bioinformatics. Community Genet, in press.
7.
Petrou B, Modell B, Shetty S, Ward RHT: Long-term effects of prospective detection of high genetic risk on couples’ reproductive life: Data for thalassaemia. Prenat Diagn, in press.
8.
Verlinsky Y, Juliev AM: An Atlas of Pre-Implantation Genetic Diagnosis. New York, Parthenon Publishing, 2000.
9.
WHO: Report of the first annual meeting of the WHO Working Group on community control of hereditary anaemias. Erice, Sicily, Oct 1982, unpubl WHO document (HMG/WG/82.2).
10.
Cao A: Results of programmes for antenatal detection of thalassaemia in reducing the incidence of the disorder. Blood Rev 1987;1:169–176.
11.
Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassaemia major. Lancet 1989;ii:27–30.
12.
Maggio A, Caronia F, Orlandi F: Prenatal diagnosis of haemoglobinopathies in Sicily. Lancet 1992;339:1361–1362.
13.
Loukopoulos D: Current status of thalassaemia and the sickle cell syndromes in Greece. Semin Hematol 1996;33:76–86.
14.
Modell B, Khan M, Darlison M: Survival in beta thalassaemia major in the United Kingdom: Data from the UK Thalassaemia Register. Lancet, in press.
15.
Modell B, Petrou M, Layton M, Varnavides L, Slater C, Ward RHT, Rodeck C, Nicolaides K, Gibbons S, Old J: Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: The first 20 years. Br Med J 1997;315:779–784.
16.
Guideline: The laboratory diagnosis of haemoglobinopathies. (Prepared by a working party of the General Haematology Task Force of the British Committee for Standards in Haematology.) Br J Haematol 1998;101:783–792.
17.
Sickle Cell, Thalassaemia and other haemoglobinopathies. Report of a Working Party of the Standing Medical Advisory Committee. London, Her Majesty’s Stationery Office, 1994.
18.
Modell B, Kuliev AM, Wagner M: Community Genetics Services in Europe. WHO Regional Publications, European Series No 38. Copenhagen, WHO Regional Office for Europe, 1992.
19.
Harris R: How well do we manage families with genetic problems? A national confidential enquiry into counselling for genetic disorders should tell us. Br Med J 1991;303:1412–1413.
20.
National Confidential Enquiry into Counselling for Genetic Disorders: Homozygous Beta Thalassaemias, Great Britain 1990–94. Report to the Department of Health from the Steering Committee, 1998.
21.
Modell B, Harris R, Lane B, Khan M, Darlison M, Petrou M, Old J, Layton M, Varnavides L: Informed choice in genetic screening for thalassaemia during pregnancy: Audit from a national confidential enquiry. Br Med J 2000;320:325–390.
22.
Health Education Authority: Sickle Cell and Thalassaemia: Achieving Health Gain. Guidance for Commissioners and Providers. (Annex 1 contains tables of ethnic minority residents and births, and indicators for services for haemoglobin disorders, for the whole UK by District Health Authority.) London, Health Education Authority, 1998.
23.
Old JM, Varawalla NY, Weatherall DJ: Rapid detection and prenatal diagnosis of beta-thalassaemia: Studies in Indian and Cypriot populations in the UK. Lancet 1990;336:834–837.
24.
Neuenschwander H, Modell B: The Process of antenatal sickle cell screening at a North London hospital. Br Med J 1997;315:784–785.
25.
Harris HJ, Scotcher D, Craufurd D, Wallace A, Harris R: Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet 1992;339:1539.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.